Navigation Links
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Date:11/28/2008

ieved to potentiate the activity of these chemicals in the central nervous system (brain and spinal cord). While the exact mechanism of action of Duloxetine is unknown, scientists believe its effects on depression and anxiety symptoms, as well as its effect on pain perception, may be due to increasing the activity of serotonin and norepinephrine in the central nervous system.

Duloxetine is approved in the United States for the acute and maintenance treatment of major depressive disorder, the acute treatment of generalized anxiety disorder, and the management of diabetic peripheral neuropathic pain and fibromyalgia in adults age 18 years and older. Duloxetine is not approved for use in pediatric patients.

Important Safety Information

Duloxetine is approved to treat major depressive disorder and generalized anxiety disorder, and to manage diabetic peripheral neuropathic pain and fibromyalgia. Antidepressants can increase suicidal thoughts and behaviors in children, adolescents, and young adults. Patients should call their doctor right away if they experience new or worsening depression symptoms, unusual changes in behavior, or thoughts of suicide. Be especially observant within the first few months of treatment or after a change in dose. Duloxetine is approved only for adults 18 and over.

Duloxetine is not for everyone. Patients should not take Duloxetine if they have recently taken a type of antidepressant called a monoamine oxidase inhibitor (MAOI), are taking Mellaril(R) (thioridazine), or have uncontrolled glaucoma. Patients should speak with their doctor about any medical conditions they may have including kidney problems, glaucoma, or diabetes. Patients should talk to their doctor if they have itching, right upper belly pain, dark urine, yellow skin or eyes, or unexplained flu-like symptoms, which may be signs of liver problems. Severe liver problems, sometimes fatal, have been repor
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
3. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
4. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
5. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
6. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
7. Lilly and TransPharma Medical Announce Licensing and Development Agreement
8. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
9. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
10. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
11. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 This September ... in Las Vegas for ... by educator, author, forward thinker and private practitioner Dr. ... experts together to candidly discuss clinical and practice management ... event is a unique opportunity to welcome fresh thinking ...
(Date:7/23/2014)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that ... and year ended June 30, 2014, on Thursday, August 7, ... conference call at 4:30 p.m. Eastern Time to discuss the ... Conference Call Details To access the live conference ... via phone, please dial 866-953-6859 from the United ...
(Date:7/23/2014)... , July 23, 2014  Silk Road Medical, ... transcarotid treatment of intra- and extra-cranial cerebrovascular disease, ... Wallace to the position of Chief Technology ... the company,s Research and Development efforts across its ... Prior to joining Silk Road Medical, ...
Breaking Medicine Technology:2014 DOCtalk Registration Now Open 22014 DOCtalk Registration Now Open 3Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3
... June 13 , - Lack of Physician Education May ... patients and physicians shows that,fibromyalgia, a chronic widespread pain condition, ... on patients often resulting in an,inability to work and earn ... fact that in most countries it takes patients on,average, 1.9 ...
... On Friday, Inspire,Pharmaceuticals (Nasdaq: ISPH ) announced ... with denufosol tetrasodium inhalation solution,delivered via PARI,s LC ... of cystic fibrosis (CF)., "We are pleased ... that,Inspire,s denufosol tetrasodium inhalation solution delivered via PARI,s ...
Cached Medicine Technology:New Global Survey Exposes Considerable Burden of Fibromyalgia Including Potential Economic Impact 2New Global Survey Exposes Considerable Burden of Fibromyalgia Including Potential Economic Impact 3New Global Survey Exposes Considerable Burden of Fibromyalgia Including Potential Economic Impact 4Inspire's Phase 3 CF Trial, Using PARI's Nebulizer & Compressor, Shows Positive Top-Line Results 2
(Date:7/23/2014)... California (PRWEB) July 23, 2014 World ... home-delivered fully prepared healthy gourmet cuisine, received rave reviews ... the LA’s Largest Mixer. Mixer attendees were amazed that ... July 17th 2014, World Gardens Café, the premier provider ... cuisine, had a booth at Dave Linden’s LA’s Largest ...
(Date:7/23/2014)... 23, 2014 Daily Face & Body is ... safer alternative to Botox called Stem Cell Technology Facial ... anti-aging product used to help people smooth, tone, and rejuvenate ... be used as a safe alternative to Botox, a popular ... toxins or health risks as opposed to Botox. In addition, ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 On July 19 ... awareness at the NBC 4 New York and New York ... East Rutherford, NJ. , The team, which included ... main sponsor, offered free hearing health screenings and answered any ... advanced hearing technology. , Also sponsored by the ...
(Date:7/23/2014)... According to the latest market reports compiled ... region, the Northern Virginia real estate market ... quickly throughout the area, and median sale prices have ... Virginia market includes the city of Alexandria, and Arlington, ... Virginia region saw median sale prices increase in some ...
(Date:7/23/2014)... Once viewed with suspicion as a New Age ... $14 billion-a-year business and arguably the most successful segment ... Way We Die , award-winning journalists Fran Smith and ... population and their families. It’s the first book to ... the stories of patients, caregivers and cutting-edge researchers, as ...
Breaking Medicine News(10 mins):Health News:Healthy Food Gets Rave Reviews at LA’s Largest Mixer 2Health News:Local Denver Skin Care Company Releases Safer Alternative to Botox 2Health News:The HearStrong Foundation Provides Hearing Healthcare Awareness at the NBC 4 New York and New York Giants Health & Fitness Expo 2014 2Health News:Northern Virginia Real Estate Company Pasquali Realty Group Announces Median Sale Price Increased in the Region in June 2014 2Health News:Dealing with Loss: Library Journal Calls Changing the Way We Die an Essential Read 2
... North Carolina State University have shown that silencing a ... carcinogens in cured tobacco leaves. , The finding could ... with reduced amounts of cancer-causing agents. , NC State,s ... Ramsey Lewis, assistant professor of crop science, teamed with ...
... will begin publishing a new peer-reviewed journal, Neuroethics, in March ... forum for interdisciplinary studies in neuroethics and related issues in ... online access to the full text of all articles during ... medium in the ethics of neuroscience and the neuroscience of ...
... Quinlan, mother of Karen Ann Quinlan, whose legal battle ... use of life-support for the dying, will present the ... John Gregory from Overlook Hospital, Summit, N.J., and posthumously ... from the Center for Hope Hospice, Scotch Plains, N.J., ...
... Consumer-Driven Plans Have Household Incomes,Over $100,000 a Year, ... high-deductible health plans increased in 2007, but,still makes ... market, according,to the third EBRI/Commonwealth Fund Consumerism in ... with a tax-advantaged,account was 2 percent of the ...
... Barr,Pharmaceuticals, Inc. (NYSE: BRL ), today confirmed ... to Deutsche Bank, acting as PLIVA,s GDR,Depositary, on ... effective June 19, 2008 ("Termination Date"). Once the ... delist from the London,Stock Exchange ("LSE"), a process ...
... Announces Internal Controls and Procedures Improvements, Corporate, Governance ... MCLEAN, Va., March 18 Sunrise Senior Living,Inc. (NYSE: ... the New York Stock,Exchange ("NYSE") that the Company did ... for filing its 2006 Form 10-K. The Company also,announced ...
Cached Medicine News:Health News:Gene 'knockout' floors tobacco carcinogen 2Health News:Springer to publish new journal focusing on ethical issues in neuroscience 2Health News:Julia Quinlan to present awards at a conference hosted by Rutgers College of Nursing 2Health News:New EBRI/Commonwealth Fund Research: Enrollment in Consumer-Driven Plans Remains Low, Survey Shows 2Health News:New EBRI/Commonwealth Fund Research: Enrollment in Consumer-Driven Plans Remains Low, Survey Shows 3Health News:New EBRI/Commonwealth Fund Research: Enrollment in Consumer-Driven Plans Remains Low, Survey Shows 4Health News:Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange 2Health News:Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange 3Health News:Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange 4Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 2Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 3Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 4Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 5Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 6Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 7Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 8Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 9
... Tamtron PowerPath is IMPACs comprehensive ... anatomic pathology laboratories to integrate and ... needs through a single, intuitive software ... more than 350 institutions have proven ...
The most compact revolutionary innovation in hematology. 8 or 18 automated parameter hematology analyzer....
... The remote vision controls all ... chart projector from the wireless ... autorefraction measurements can be loaded ... wireless data transfer. The illuminated ...
... ultimate in clinical color vision tests. It ... red/green or blue/yellow color vision losses that ... from Plaquenil, for example), early optic neuritis, ... it is fast and accurate in quantifying ...
Medicine Products: